دورية أكاديمية
أعرض في EDS

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment.

التفاصيل البيبلوغرافية
العنوان: Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment.
المؤلفون: Ghasemi Darestani N; Isfahan University of Medical Sciences, Isfahan, Iran., Gilmanova AI; Department of Prosthetic Dentistry of the I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation., Al-Gazally ME; College of Medicine, University of Al-Ameed, Karbala, Iraq., Zekiy AO; Department of Prosthetic Dentistry of the I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation., Ansari MJ; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia., Zabibah RS; Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq., Jawad MA; Al-Nisour University College, Baghdad, Iraq., Al-Shalah SAJ; Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Iraq., Rizaev JA; Department of Public Health and Healthcare Management, Rector, Samarkand State Medical University, Samarkand, Uzbekistan., Alnassar YS; The University of Mashreq, Baghdad, Iraq., Mohammed NM; Department of Pharmacy, Mazaya University College, Nasiriyah, Dhi Qar, Iraq., Mustafa YF; Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq., Darvishi M; Department of Aerospace and Subaquatic Medicine, Infectious Diseases and Tropical Medicine Research Center (IDTMRC), AJA University of Medical Sciences, Tehran, Iran. darvishi1349@gmail.com., Akhavan-Sigari R; Department of Neurosurgery, University Medical Center, Tuebingen, Germany.; Department of Health Care Management and Clinical Research, Collegium Humanum Warsaw Management University, Warsaw, Poland.
المصدر: Cell communication and signaling : CCS [Cell Commun Signal] 2023 Feb 24; Vol. 21 (1), pp. 43. Date of Electronic Publication: 2023 Feb 24.
نوع المنشور: Video-Audio Media; Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101170464 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-811X (Electronic) Linking ISSN: 1478811X NLM ISO Abbreviation: Cell Commun Signal Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, c2003-
مواضيع طبية MeSH: Oncolytic Viruses*/physiology , Oncolytic Virotherapy*/methods , Neoplasms*/pathology , Mesenchymal Stem Cells*/pathology, Humans ; Immunotherapy ; Tumor Microenvironment
مستخلص: Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no damage to normal cells in the process. Because of their specific features, such as, the ability to induce immunogenic cell death and to contain curative transgenes in their genomes, OVs have attracted attention as candidates to be utilized in cooperation with immunotherapies for cancer treatment. This treatment takes advantage of most tumor cells' inherent tendency to be infected by certain OVs and both innate and adaptive immune responses are elicited by OV infection and oncolysis. OVs can also modulate tumor microenvironment and boost anti-tumor immune responses. Mesenchymal stem cells (MSC) are gathering interest as promising anti-cancer treatments with the ability to address a wide range of cancers. MSCs exhibit tumor-trophic migration characteristics, allowing them to be used as delivery vehicles for successful, targeted treatment of isolated tumors and metastatic malignancies. Preclinical and clinical research were reviewed in this study to discuss using MSC-released OVs as a novel method for the treatment of cancer. Video Abstract.
(© 2023. The Author(s).)
References: Biomedicines. 2016 Jul 07;4(3):. (PMID: 28536380)
Nat Rev Drug Discov. 2019 Sep;18(9):689-706. (PMID: 31292532)
Hum Gene Ther. 2004 Apr;15(4):351-60. (PMID: 15053860)
PLoS One. 2015 Oct 19;10(10):e0139870. (PMID: 26479722)
Breast Cancer Res Treat. 2007 Oct;105(2):157-67. (PMID: 17221158)
Nat Rev Immunol. 2008 Jul;8(7):559-68. (PMID: 18575461)
Methods Mol Biol. 2020;2058:1-6. (PMID: 31486028)
J Clin Oncol. 2015 Sep 1;33(25):2812-4. (PMID: 26215964)
Nat Rev Cancer. 2014 Oct;14(10):683-91. (PMID: 25176333)
Oncotarget. 2016 Feb 23;7(8):9046-59. (PMID: 26824985)
Biomedicines. 2021 May 13;9(5):. (PMID: 34068264)
Nat Biotechnol. 2012 Jul 10;30(7):658-70. (PMID: 22781695)
Cell Cycle. 2009 Jul 15;8(14):2194-7. (PMID: 19502787)
Blood. 2014 Feb 27;123(9):1327-35. (PMID: 24345754)
Cancer Res. 2009 Dec 1;69(23):8932-40. (PMID: 19920199)
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7. (PMID: 19264968)
Stem Cells Transl Med. 2015 Mar;4(3):239-51. (PMID: 25646527)
Front Immunol. 2018 Apr 26;9:866. (PMID: 29755464)
J Clin Oncol. 2015 Sep 1;33(25):2780-8. (PMID: 26014293)
Clin Cancer Res. 2013 May 15;19(10):2734-44. (PMID: 23493351)
J Exp Med. 2006 May 15;203(5):1235-47. (PMID: 16636132)
Adv Virol. 2012;2012:805629. (PMID: 22400027)
Biomedicines. 2019 Aug 30;7(3):. (PMID: 31480379)
Nat Clin Pract Oncol. 2008 May;5(5):280-90. (PMID: 18349857)
Mol Ther. 2013 Feb;21(2):338-47. (PMID: 23299799)
Mol Ther Oncolytics. 2019 Mar 20;13:14-21. (PMID: 30997392)
Cancer Res. 2008 Jun 15;68(12):4882-92. (PMID: 18559536)
Cancer Immunol Immunother. 2018 Jun;67(6):999-1009. (PMID: 29487978)
Mol Ther. 2009 Oct;17(10):1667-76. (PMID: 19690519)
Cancer Gene Ther. 2007 Jul;14(7):627-39. (PMID: 17479104)
Toxicol Appl Pharmacol. 2017 Nov 15;335:56-63. (PMID: 28974455)
J Cell Biochem. 2016 Sep;117(9):2045-55. (PMID: 27392313)
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51. (PMID: 11070094)
Hepatology. 2004 Dec;40(6):1304-11. (PMID: 15565662)
Stem Cells. 2011 Jan;29(1):11-9. (PMID: 21280155)
Oncoimmunology. 2014 Dec 13;3(9):e955691. (PMID: 25941621)
Oncogene. 2005 Nov 21;24(52):7802-16. (PMID: 16299539)
Gene Ther. 2004 Jul;11(14):1155-64. (PMID: 15141157)
Nat Neurosci. 2011 Dec 25;15(2):197-204. (PMID: 22197831)
Biomed Pharmacother. 2020 Jul;127:110098. (PMID: 32299028)
Gene Ther. 2013 Jan;20(1):7-15. (PMID: 22170342)
Biomed Pharmacother. 2022 Apr;148:112735. (PMID: 35193040)
Thorac Cancer. 2019 May;10(5):1031-1035. (PMID: 30900824)
Expert Opin Ther Pat. 2021 May;31(5):435-452. (PMID: 33347360)
PLoS One. 2012;7(2):e30563. (PMID: 22363446)
Biochem J. 2010 Apr 28;428(1):11-23. (PMID: 20423328)
Stem Cells Int. 2017;2017:3615729. (PMID: 28781596)
Oncoimmunology. 2014 Jul 03;3(7):e947872. (PMID: 25954598)
Cancer Lett. 2016 Feb 28;371(2):161-70. (PMID: 26655276)
Mol Ther Methods Clin Dev. 2020 Jan 15;17:349-358. (PMID: 32071927)
Gene Ther. 2013 Nov;20(11):1033-41. (PMID: 23719065)
Cytotherapy. 2009;11(3):289-98, 1 p following 298. (PMID: 19308770)
Nat Med. 2013 Mar;19(3):329-36. (PMID: 23396206)
Clin Cancer Res. 2013 Mar 1;19(5):1147-58. (PMID: 23339127)
Adv Pharm Bull. 2021 Feb;11(2):361-370. (PMID: 33880359)
Nat Clin Pract Oncol. 2007 Feb;4(2):101-17. (PMID: 17259931)
Oncolytic Virother. 2015 Nov 11;4:169-81. (PMID: 27512680)
Adv Wound Care (New Rochelle). 2012 Aug;1(4):147-152. (PMID: 24527296)
Hum Gene Ther. 2007 Jul;18(7):627-41. (PMID: 17604566)
Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. (PMID: 18925850)
Nat Biotechnol. 2000 Jul;18(7):723-7. (PMID: 10888838)
Cancers (Basel). 2022 Apr 16;14(8):. (PMID: 35454928)
Oncotarget. 2015 Jun 30;6(18):16019-30. (PMID: 25909216)
Cancer Gene Ther. 2010 Jul;17(7):476-83. (PMID: 20168350)
Immunol Rev. 2017 Nov;280(1):126-148. (PMID: 29027218)
Immunol Cell Biol. 2016 Apr;94(4):342-56. (PMID: 26510892)
Front Immunol. 2018 Dec 21;9:3018. (PMID: 30622535)
Br J Cancer. 2008 Aug 19;99(4):622-31. (PMID: 18665180)
Cell Biol Int. 2008 Jan;32(1):8-15. (PMID: 17904875)
Hum Gene Ther. 1997 Mar 20;8(5):597-613. (PMID: 9095411)
Trends Mol Med. 2013 Jun;19(6):378-92. (PMID: 23540715)
Stem Cells Dev. 2017 Nov 15;26(22):1648-1661. (PMID: 28946811)
Front Oncol. 2017 Sep 08;7:195. (PMID: 28944214)
Gene. 2013 Aug 10;525(2):208-16. (PMID: 23542073)
J Immunol. 2012 Aug 1;189(3):1182-92. (PMID: 22753940)
Chin J Cancer. 2012 May;31(5):233-40. (PMID: 22429494)
Lancet Oncol. 2008 Apr;9(4):376-84. (PMID: 18374291)
Cancer Immunol Immunother. 2017 Oct;66(10):1249-1264. (PMID: 28712033)
Int J Cancer. 2020 Jan 15;146(2):531-541. (PMID: 31584185)
Hum Gene Ther. 2016 Apr;27(4):325-37. (PMID: 26993072)
Ann Neurol. 2005 Jan;57(1):34-41. (PMID: 15622535)
Front Pharmacol. 2018 Nov 22;9:1371. (PMID: 30524291)
Sensors (Basel). 2021 Dec 24;22(1):. (PMID: 35009640)
Cell Death Dis. 2016 Jan 21;7:e2062. (PMID: 26794657)
Cell Rep. 2016 Apr 12;15(2):274-87. (PMID: 27050509)
BioDrugs. 2019 Oct;33(5):485-501. (PMID: 31321623)
Front Immunol. 2018 Dec 21;9:3053. (PMID: 30622539)
Stem Cell Res Ther. 2016 Nov 10;7(1):163. (PMID: 27832825)
Oncotarget. 2017 Jul 11;8(28):45415-45431. (PMID: 28525366)
Nat Commun. 2018 Apr 12;9(1):1410. (PMID: 29650952)
Front Immunol. 2019 Jun 06;10:1288. (PMID: 31244839)
Cancers (Basel). 2021 Mar 19;13(6):. (PMID: 33808692)
Discov Med. 2010 Mar;9(46):192-6. (PMID: 20350484)
Mol Ther Oncolytics. 2022 Feb 01;24:486-496. (PMID: 35229027)
Mol Ther. 2015 Apr;23(4):746-56. (PMID: 25619723)
Cancer Lett. 2019 Sep 28;460:108-118. (PMID: 31226409)
Stem Cells Transl Med. 2017 Apr;6(4):1120-1131. (PMID: 28205428)
Stem Cells Transl Med. 2016 Nov;5(11):1506-1514. (PMID: 27400792)
J Virol. 2010 Apr;84(8):3835-44. (PMID: 20147405)
Cancer Gene Ther. 2002 Dec;9(12):967-78. (PMID: 12522436)
Mol Ther. 2011 Feb;19(2):335-44. (PMID: 21119618)
Clin Cancer Res. 2009 Dec 1;15(23):7246-55. (PMID: 19934299)
Int Immunopharmacol. 2021 May;94:107437. (PMID: 33571747)
Life Sci. 2021 Dec 15;287:120056. (PMID: 34687756)
Curr Opin Mol Ther. 2009 Feb;11(1):43-53. (PMID: 19169959)
Blood. 2008 Feb 1;111(3):1327-33. (PMID: 17951526)
Front Cell Dev Biol. 2019 Apr 16;7:50. (PMID: 31041312)
World J Stem Cells. 2016 Mar 26;8(3):73-87. (PMID: 27022438)
Front Immunol. 2019 Aug 07;10:1848. (PMID: 31440242)
Mol Ther. 2010 Jan;18(1):223-31. (PMID: 19844197)
J Cell Biochem. 2015 Apr;116(4):618-27. (PMID: 25399738)
Sci Rep. 2015 Nov 20;5:16941. (PMID: 26585689)
Clin Cancer Res. 2021 Mar 15;27(6):1766-1777. (PMID: 33272983)
Gene. 2022 Nov 30;844:146829. (PMID: 35995118)
IUBMB Life. 2022 Sep;74(9):908-917. (PMID: 35638098)
Invest New Drugs. 2015 Jun;33(3):761-74. (PMID: 25693885)
Cell Transplant. 2015;24(4):625-30. (PMID: 25310691)
J Control Release. 2019 Jul 10;305:75-88. (PMID: 31071373)
Mol Ther. 2013 Jun;21(6):1212-23. (PMID: 23546299)
J Biol Chem. 2011 Jul 29;286(30):26319-26. (PMID: 21636578)
Gene Ther. 2008 May;15(10):716-29. (PMID: 18369326)
Viruses. 2010 Jan;2(1):78-106. (PMID: 20543907)
Expert Rev Vaccines. 2010 Nov;9(11):1275-302. (PMID: 21087107)
Cell Mol Immunol. 2017 Jan 02;:. (PMID: 28042143)
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):843-53. (PMID: 18849123)
Cell Mol Life Sci. 1999 Apr;55(4):663-7. (PMID: 10357234)
Mol Ther Oncolytics. 2020 Jul 06;18:335-350. (PMID: 32775618)
Front Oncol. 2014 Apr 10;4:74. (PMID: 24782985)
Comput Biol Med. 2021 Nov 29;140:105092. (PMID: 34864302)
Nat Commun. 2022 Jun 27;13(1):3676. (PMID: 35760796)
Nat Rev Cancer. 2005 Dec;5(12):965-76. (PMID: 16294217)
Anticancer Drugs. 2003 Sep;14(8):577-84. (PMID: 14501378)
J Natl Cancer Inst. 2014 May 16;106(6):dju090. (PMID: 24838834)
Mol Ther Oncolytics. 2018 Oct 18;11:62-74. (PMID: 30505937)
Biochem Pharmacol. 2020 Dec;182:114224. (PMID: 32956642)
Future Oncol. 2015;11(4):675-89. (PMID: 25686121)
J Cell Biochem. 2021 Oct;122(10):1360-1375. (PMID: 34056765)
Cancer Lett. 2011 Dec 15;312(1):1-10. (PMID: 21906874)
Nature. 2007 Oct 4;449(7162):557-63. (PMID: 17914389)
J Hepatol. 2013 Nov;59(5):999-1006. (PMID: 23867315)
Hum Gene Ther. 2003 Feb 10;14(3):227-41. (PMID: 12639303)
Front Oncol. 2022 Apr 19;12:818447. (PMID: 35515137)
Cell Res. 2008 Apr;18(4):500-7. (PMID: 18364678)
Mol Cancer. 2011 Nov 03;10:134. (PMID: 22054049)
J Cell Physiol. 2018 Apr;233(4):2902-2910. (PMID: 28543172)
Biomed Res Int. 2019 May 8;2019:2820853. (PMID: 31205939)
Cancer Res. 2014 Dec 15;74(24):7260-73. (PMID: 25336188)
Nat Rev Clin Oncol. 2018 Mar;15(3):135. (PMID: 29384144)
Anticancer Res. 2015 Jan;35(1):159-68. (PMID: 25550547)
Cancer Res. 2019 Sep 1;79(17):4503-4514. (PMID: 31289131)
Blood. 2005 May 15;105(10):4120-6. (PMID: 15692068)
Biochem Pharmacol. 2021 Aug;190:114644. (PMID: 34090878)
Front Immunol. 2022 Mar 03;13:839945. (PMID: 35309327)
Cancer Res. 2008 May 15;68(10):3795-802. (PMID: 18483263)
Cancer Biol Ther. 2008 Aug;7(8):1194-205. (PMID: 18458533)
Mol Ther. 2020 Apr 8;28(4):1033-1042. (PMID: 32053771)
Nat Rev Cancer. 2014 Aug;14(8):559-67. (PMID: 24990523)
Cancer Gene Ther. 2020 May;27(5):383-388. (PMID: 31204390)
Cell Transplant. 2015;24(12):2585-99. (PMID: 25695620)
Adv Sci (Weinh). 2021 Feb 25;8(9):2003535. (PMID: 33977050)
J Cell Mol Med. 2020 May;24(10):5817-5831. (PMID: 32283569)
J Hepatol. 2012 Sep;57(3):556-63. (PMID: 22617153)
Breast Cancer Res Treat. 2006 Sep;99(2):177-84. (PMID: 16642271)
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):127-34. (PMID: 20399700)
Blood. 2006 Jan 1;107(1):367-72. (PMID: 16141348)
Gynecol Oncol. 2013 Sep;130(3):518-24. (PMID: 23756180)
Cancer Gene Ther. 2008 Apr;15(4):231-40. (PMID: 18202717)
Stem Cell Res Ther. 2017 Mar 9;8(1):58. (PMID: 28279201)
J Immunol. 2018 Jan 15;200(2):450-458. (PMID: 29311387)
Mol Ther. 2010 Feb;18(2):243-50. (PMID: 19935777)
Stem Cells. 2008 Mar;26(3):831-41. (PMID: 18192232)
Front Oncol. 2017 May 23;7:106. (PMID: 28589085)
Trends Immunol. 2018 Mar;39(3):209-221. (PMID: 29275092)
Methods Mol Biol. 2020;2058:191-211. (PMID: 31486039)
Mol Ther. 2010 Feb;18(2):377-85. (PMID: 19904233)
Oncol Rep. 2013 Jan;29(1):199-204. (PMID: 23129111)
J Biomed Sci. 2019 Jun 19;26(1):48. (PMID: 31217023)
J Clin Med. 2021 Jun 29;10(13):. (PMID: 34210026)
Nat Rev Cancer. 2016 Aug 23;16(9):582-98. (PMID: 27550820)
Adv Drug Deliv Rev. 2012 Jun 1;64(8):739-48. (PMID: 21740940)
Eur J Immunol. 2016 Apr;46(4):919-28. (PMID: 26763072)
Nat Rev Cancer. 2018 Jul;18(7):419-432. (PMID: 29695749)
Cell Host Microbe. 2014 Mar 12;15(3):260-5. (PMID: 24629333)
PLoS One. 2014 Mar 20;9(3):e92919. (PMID: 24651853)
Mol Ther. 2009 Sep;17(9):1626-36. (PMID: 19532135)
Oncoimmunology. 2014 Jun 01;3:e28694. (PMID: 25097804)
Breast Cancer Res Treat. 2010 Nov;124(2):317-26. (PMID: 20087650)
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6157-E6165. (PMID: 28710334)
Gene Ther. 2006 Jun;13(12):986-90. (PMID: 16525485)
Cancer Biother Radiopharm. 2009 Dec;24(6):717-21. (PMID: 20025552)
Stem Cell Res Ther. 2016 Oct 10;7(1):149. (PMID: 27724977)
Cancer Res. 2013 Feb 15;73(4):1265-75. (PMID: 23393196)
Biotechnol Prog. 2020 Nov;36(6):e3025. (PMID: 32410328)
Mol Ther. 2007 Sep;15(9):1686-93. (PMID: 17579581)
Clin Cancer Res. 2007 May 15;13(10):2955-60. (PMID: 17504996)
J Transl Med. 2013 Jan 24;11:20. (PMID: 23347343)
J Transl Med. 2013 Mar 26;11:79. (PMID: 23531320)
Clin Exp Immunol. 2006 Nov;146(2):344-53. (PMID: 17034588)
Prostate. 2009 Jul 1;69(10):1128-41. (PMID: 19367568)
Cancer Gene Ther. 2012 Jun;19(6):431-42. (PMID: 22555507)
Blood. 2009 Apr 30;113(18):4197-205. (PMID: 19036701)
Oncotarget. 2015 Oct 27;6(33):34774-87. (PMID: 26430966)
Stem Cells Dev. 2019 Jul 1;28(13):882-896. (PMID: 30991894)
J Invest Dermatol. 2006 Nov;126(11):2525-32. (PMID: 16960554)
Oncologist. 2002;7(2):106-19. (PMID: 11961194)
Cancer Lett. 2021 Jul 1;509:26-38. (PMID: 33819529)
Gene Ther. 2013 Mar;20(3):255-61. (PMID: 22476202)
PLoS One. 2009;4(4):e4992. (PMID: 19352430)
Front Pharmacol. 2018 Mar 20;9:259. (PMID: 29615915)
Cytokine Growth Factor Rev. 2018 Jun;41:28-39. (PMID: 29576283)
Int J Cancer. 2014 Aug 1;135(3):720-30. (PMID: 24374597)
Methods Mol Biol. 2019;1899:3-13. (PMID: 30649761)
Oncotarget. 2020 Jan 28;11(4):347-361. (PMID: 32064039)
Cell J. 2020 Oct;22(3):283-292. (PMID: 31863653)
J Cell Biochem. 2007 May 1;101(1):135-46. (PMID: 17295203)
Biochem Biophys Res Commun. 2020 Jun 4;526(3):641-646. (PMID: 32248971)
J Cell Physiol. 2020 Jul;235(7-8):5449-5460. (PMID: 31970790)
Int J Nanomedicine. 2020 Apr 17;15:2563-2582. (PMID: 32368041)
Biomatter. 2013 Jan-Mar;3(1):. (PMID: 23507920)
Exp Cell Res. 2010 Dec 10;316(20):3417-24. (PMID: 20633553)
Gastroenterology. 2012 Dec;143(6):1555-1563.e2. (PMID: 22902870)
Mol Ther. 2009 Jan;17(1):199-207. (PMID: 18957964)
Cancer Res. 2003 May 15;63(10):2462-9. (PMID: 12750267)
Cancer Cell. 2017 Aug 14;32(2):253-267.e5. (PMID: 28810147)
Hepatology. 2006 Dec;44(6):1465-77. (PMID: 17133484)
Sensors (Basel). 2021 Dec 27;22(1):. (PMID: 35009694)
Biores Open Access. 2012 Jan;1(1):3-15. (PMID: 23515241)
Macromol Biosci. 2018 Jan;18(1):. (PMID: 28902983)
Stem Cells. 2009 Mar;27(3):670-681. (PMID: 19267325)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
Cell Mol Immunol. 2015 Nov;12(6):708-18. (PMID: 25482073)
Virol J. 2020 May 5;17(1):64. (PMID: 32370750)
Sensors (Basel). 2021 Dec 26;22(1):. (PMID: 35009681)
Mol Ther. 2010 Oct;18(10):1846-56. (PMID: 20588259)
Front Oncol. 2017 Sep 11;7:202. (PMID: 28955655)
Transplant Proc. 2007 Mar;39(2):573-6. (PMID: 17362785)
Blood. 2001 Oct 1;98(7):2002-7. (PMID: 11567982)
Mol Ther. 2021 May 5;29(5):1808-1820. (PMID: 33571680)
Stem Cell Res Ther. 2022 Sep 24;13(1):482. (PMID: 36153626)
J Nephropathol. 2017 Jan;6(1):1-4. (PMID: 28042546)
Curr Immunol Rev. 2010 May 1;6(2):137-148. (PMID: 20490366)
Mol Ther. 2015 Sep;23(9):1497-506. (PMID: 26084970)
Hum Gene Ther. 2003 Sep 1;14(13):1247-54. (PMID: 12952596)
Breast Cancer Res Treat. 2010 Aug;122(3):745-54. (PMID: 19894113)
Cancer Microenviron. 2015 Apr;8(1):1-14. (PMID: 25169041)
Ann Oncol. 2018 Jan 1;29(1):71-83. (PMID: 29069302)
Stem Cells. 2016 Oct;34(10):2536-2547. (PMID: 27300750)
Mol Ther. 2009 Jan;17(1):51-6. (PMID: 18957963)
Cell Death Dis. 2018 Oct 8;9(10):1026. (PMID: 30297887)
Mol Ther Oncolytics. 2019 Nov 02;15:234-247. (PMID: 31872046)
Int J Cancer. 2015 Oct 1;137(7):1775-83. (PMID: 25821063)
Methods. 2016 Apr 15;99:37-43. (PMID: 26314280)
Mol Ther. 2008 Sep;16(9):1546-55. (PMID: 18648350)
Gene Ther. 2005 Jun;12(11):902-10. (PMID: 15690062)
Cancer Res. 2006 Sep 1;66(17):8319-26. (PMID: 16951136)
Cancer Res. 2007 Nov 15;67(22):10664-8. (PMID: 18006807)
Infect Agent Cancer. 2019 Feb 11;14:5. (PMID: 30792754)
Cancer Res. 2006 Mar 15;66(6):3317-22. (PMID: 16540686)
Nat Rev Drug Discov. 2015 Sep;14(9):642-62. (PMID: 26323545)
Cancers (Basel). 2020 Jul 16;12(7):. (PMID: 32708639)
Mayo Clin Proc. 2014 Jul;89(7):926-33. (PMID: 24835528)
ACS Med Chem Lett. 2015 Dec 18;7(1):2-5. (PMID: 26819655)
Hum Gene Ther. 2000 Nov 1;11(16):2219-30. (PMID: 11084679)
Cancer Cell Int. 2022 Apr 29;22(1):168. (PMID: 35488303)
Blood. 2002 Jan 1;99(1):111-20. (PMID: 11756160)
Cancer Res. 2002 Aug 15;62(16):4656-62. (PMID: 12183422)
Cancer Res. 2017 Nov 15;77(22):6179-6189. (PMID: 28972074)
Mol Cancer Ther. 2019 Jan;18(1):127-138. (PMID: 30322950)
Mol Pharm. 2011 Oct 3;8(5):1559-72. (PMID: 21718006)
Mol Ther. 2015 Mar;23(3):602-8. (PMID: 25531693)
Mol Cancer Ther. 2006 Mar;5(3):755-66. (PMID: 16546991)
Hum Gene Ther. 2002 Sep 20;13(14):1737-50. (PMID: 12396626)
J Transl Med. 2020 Jan 30;18(1):42. (PMID: 32000804)
فهرسة مساهمة: Keywords: Cancer treatment; Cellular carriers; Mesenchymal stem cell; Oncolytic virotherapy; Oncolytic virus
تواريخ الأحداث: Date Created: 20230224 Date Completed: 20230228 Latest Revision: 20230319
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9960453
DOI: 10.1186/s12964-022-01012-0
PMID: 36829187
قاعدة البيانات: MEDLINE
الوصف
تدمد:1478-811X
DOI:10.1186/s12964-022-01012-0